BioMap
百图生科
Baidu-backed 'large biology model' company whose 100B+-parameter life-science foundation model xTrimo powers an AI-Generated Protein (AIGP) platform — now standing up its first international innovation center, BioMap InnoHub, in Hong Kong with HK government (HKIC) backing.
- Location
- BioMap InnoHub, Hong Kong (specific HKSTP/Cyberport site to be confirmed) · Hong Kong
- Visit window
- Best Jul 6–7 or Jul 11 · avoid Jul 8–10 (LEAP East)
- Source status
- medium confidencecandidate
Next action
Keep the dossier ready and use the open questions if a visit window opens.
Why now: Visit window · Best Jul 6–7 or Jul 11 · avoid Jul 8–10 (LEAP East)
What they do
Builds life-science foundation models (the xTrimo family, reportedly 100B-268B parameters across DNA, RNA, protein, cell, biological-text and biological-systems modalities) and sells access via its AIGP platform for protein design and optimisation. Reports 200+ users across MNC pharma, CDMOs, drug developers and synthetic-biology / green-tech firms — a horizontal AI-protein engine rather than a single-pipeline drug company.
In Hong Kong it is launching BioMap InnoHub plus a BioX accelerator to support 50+ early-stage life-science projects over five years. HQ is in Beijing.
Why it matters
Sits on Pure Advance's AI-driven-discovery pillar in two ways: (1) AI-protein/AI-synbio tooling — AIGP is the 'design proteins from a foundation model' capability for engineering the enzymes/proteins/strains behind microbial biocontrols, and BioMap explicitly markets to synthetic-biology, green-tech and agriculture (Syngenta, LanzaTech namechecked); (2) the BioX accelerator/ecosystem could treat a Saudi biotech with a real product as an international project, with the HK base lowering China-data/IP friction. Large and Baidu-adjacent, so best treated as relationship/tooling, approached with a concrete protein-design use case.
Visit objective & route
Explore AIGP for a concrete protein/strain-design use case, gauge BioX accelerator interest and eligibility, and confirm whether the HK InnoHub is operational and staffed for visitors.
Approach route
Treat as appointment-only (brand-new HK operation); route in via the corporate site contact form, HKIC as the named HK partner, or HKSTP/Cyberport/HKU/HKUST ecosystem contacts. Confirm the exact HK site before travelling.
Talking points
- Is AIGP genuinely usable for non-pharma / synbio / enzyme design — can you share a concrete reference case?
- Is the BioX accelerator open to a non-HK / international (e.g. Saudi) project, or HK-startups only?
- Bring a concrete strain/protein-design use case so this is more than a courtesy intro.
- Which HK site houses the InnoHub, and is it operational and staffed for visitors during the visit window?
Open questions
- Exact HK InnoHub location and whether it is operational and staffed for visitors — the single biggest open question.
- Hype check: 'world's largest model', 'beats AlphaFold 3' and parameter counts are largely company-sourced — flag as claims, not independent benchmarks.
- Whether AIGP is genuinely usable for non-pharma / synbio / enzyme design.
- The correct inbound channel (HKIC vs corporate form vs accelerator application) and BioX eligibility for an international company.
Risks & unknowns
- Large, well-funded and Baidu-adjacent — high risk of a courtesy intro without a concrete use case.
- Brand-new HK operation (since mid-2024); may be a launch/ceremony presence more than a walk-in office.
- Performance claims are company-sourced — present as claims, not verified benchmarks.
- China-data/IP considerations, partially mitigated by the HK base.
Private-pack boundary